Multidomain Lifestyle Profiles, Biomarker-Outlined Alzheimers Pathology, and Clinical Expression: Design of the HUNT-ADAPT Study

Competing Interest Statement

Holger Frohlich experiences help for the current manuscript and grants/contracts from the Innovative Health Initiative, paid to the Fraunhofer Society. Miia Kivipelto experiences grants or contracts from the Academy of Finland, Swedish Research Council, Alzheimers Research and Prevention Foundation, EU seventh Framework Programme, CIMED, JPND, IMI, Wallenberg Clinical Grant, FORTE, KI-Janssen Strategic Collaboration, Imperial College ITMAT, Innovative Health Initiative, Gates Ventures, ADDI, Alzheimers Drug Discovery Foundation, and Part the Cloud; fee or honoraria from Eisai, Eli Lilly, Novo Nordisk, and Nutricia; participation on advisory boards for BioArctic, Combinostics, Eisai, Eli Lilly, Nestle, and Roche; and management or fiduciary roles with the Board of Governors of the Alzheimers Drug Discovery Foundation and the World Dementia Council. Mark van der Giezen experiences help for the current manuscript and grants/contracts from the Innovative Health Initiative, paid to Stavanger University Hospital. Audun Osland Vik-Mo experiences help for the current manuscript from Helse Stavanger/University of Bergen and advisory board membership for Eisai. Antoine Leuzy is Founder and CEO of ZRO Imaging. Ole A. Andreassen experiences institutional help or grants from the Research Council of Norway, NordForsk, NIH, EU, KG Jebsen, Novo Nordisk, and the South-Eastern Norway Regional Health Authority; royalties from a psychiatry textbook; consulting charges from Cortechs.ai and Ledidi AS; honoraria from Lundbeck, Eli Lilly, BMS, Medice, Janssen, Otsuka, and Sunovion; advisory board participation for Ledidi; a management or fiduciary position with the Research Council of Norway; and inventory or inventory choices in Cortechs, Ledidi, and Precision Health. Geir Selbaek has participated in advisory board conferences for Eli Lilly and Eisai relating to disease-modifying medication for Alzheimers illness, and has obtained honoraria for lectures at symposia sponsored by Eisai and Eli Lilly. Dag Aarsland has obtained analysis help and/or honoraria from Evonik, Roche Diagnostics, GE Health, and Sanofi, and has served as a paid advisor for Eisai, BioArctic, Eli Lilly, Enterin, Roche Diagnostics, Acadia, GSK, EIP Pharma, Biogen, Takeda, Zylvan, and Discoveric Alpha Consulting. The remaining authors declare no conflicts of curiosity.
Acknowledgment
The Trondelag Health Study (HUNT) is a collaboration between HUNT Research Centre, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. We thank the inhabitants of Trondelag for his or her willingness to contribute necessary knowledge and organic materials, and the workers at HUNT Research Centre and collaborating establishments for his or her contributions to the planning, assortment, storage, and administration of HUNT knowledge and organic materials. The Norwegian National Centre for Ageing and Health contributed to the funding of the HUNT4 70+ survey and funded the Ageing in Trondelag (AiT) examine. The HUNT4 70+ survey obtained extra funding from the Center for Oral Health Services and Research, Trondheim. The genetic investigations of the HUNT Study are a collaboration between researchers from the Okay.G. Jebsen Center for Genetic Epidemiology, NTNU, and the University of Michigan, with SNP genotyping carried out by the Genomics Core Facility at NTNU.
Funding
This work is supported by ACCESS-AD, inner help from the Centre for Age-Related Medicine (SESAM), and in-kind contributions from PhD candidates, postdoctoral researchers, and principal investigators.

Author Declarations

I affirm all related moral tips have been adopted, and any obligatory IRB and/or ethics committee approvals have been obtained.

Yes

I affirm that each one obligatory affected person/participant consent has been obtained and the suitable institutional types have been archived, and that any affected person/participant/pattern identifiers included weren’t identified to anybody (e.g., hospital workers, sufferers or members themselves) outdoors the analysis group so can’t be used to determine people.

Yes

I perceive that each one medical trials and another potential interventional research have to be registered with an ICMJE-approved registry, corresponding to ClinicalTrials.gov. I affirm that any such examine reported within the manuscript has been registered and the trial registration ID is supplied (word: if posting a potential examine registered retrospectively, please present a press release within the trial ID area explaining why the examine was not registered upfront).

Yes

I’ve adopted all acceptable analysis reporting tips, corresponding to any related EQUATOR Network analysis reporting guidelines(s) and different pertinent materials, if relevant.

Yes